(Q34763003)

4 August 2017

Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization (English)

1 reference

4 August 2017

1 reference

Johan P Rung

1

1 reference

4 August 2017

Emilia Rung

2

1 reference

4 August 2017

Lisa Helgeson

3

1 reference

4 August 2017

Anette M Johansson

4

1 reference

4 August 2017

Kjell Svensson

5

1 reference

4 August 2017

Arvid Carlsson

6

1 reference

4 August 2017

Maria L Carlsson

7

1 reference

4 August 2017

20 March 2008

1 reference

Journal of Neural Transmission

4 August 2017

1 reference

4 August 2017

115

1 reference

4 August 2017

6

1 reference

4 August 2017

899-908

1 reference

https://scigraph.springernature.com/pub.10.1007/s00702-008-0038-3

4 August 2017

0 references

cites work

The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Schizophrenia: from dopamine to glutamate and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

How does the benzamide antipsychotic amisulpride get into the brain?--An in vitro approach comparing amisulpride with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: implications for the identity of dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

(+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0038-3

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity

21 January 2018

1 reference

12 December 2020

Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour

1 reference

12 December 2020

A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel lecture).

1 reference

12 December 2020

Dopamine receptor agonists: intrinsic activity vs. state of receptor

1 reference

12 December 2020

The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity

1 reference

12 December 2020

Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding

1 reference

12 December 2020

Real-time assessments of dopamine function during behavior: single-unit recording, iontophoresis, and fast-scan cyclic voltammetry in awake, unrestrained rats

1 reference

12 December 2020

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

1 reference

12 December 2020

10.1007/S00702-008-0038-3

Identifiers

DOI

1 reference

4 August 2017

1 reference